Comparison between patients with or without deletion 13 after dose-reduced allograft
. | Deletion 13; n = 31 . | No deletion 13; n = 37 . | P . |
|---|---|---|---|
| Median days of leukocyte count higher than 1.0 × 109/L | 13 | 13 | .4 |
| Median days of platelet count higher than 20 × 109/L | 19 | 16 | .3 |
| Platelet substitution, mean package | 11 | 9 | .2 |
| Acute GVHD grades II-IV, % | 43 | 36 | .5 |
| Chronic GVHD, % | 26 | 27 | .9 |
| CR after allograft, n (%) | 9 (31) | 11 (35) | .7 |
| No response after allograft, n (%) | 8 (28) | 4 (13) | .3 |
| 2 years overall survival, % (95% CI) | 18 (0-38) | 67 (51-83) | .03 |
| 2 years event-free survival, % (95% CI) | 18 (1-35) | 42 (24-60) | .05 |
| Cumulative incidence of relapse, % (95% CI) | 77 (57-97) | 44 (22-66) | < .001 |
| 1 year treatment-related mortality, % (95% CI) | 18 (4-32) | 24 (10-38) | .4 |
. | Deletion 13; n = 31 . | No deletion 13; n = 37 . | P . |
|---|---|---|---|
| Median days of leukocyte count higher than 1.0 × 109/L | 13 | 13 | .4 |
| Median days of platelet count higher than 20 × 109/L | 19 | 16 | .3 |
| Platelet substitution, mean package | 11 | 9 | .2 |
| Acute GVHD grades II-IV, % | 43 | 36 | .5 |
| Chronic GVHD, % | 26 | 27 | .9 |
| CR after allograft, n (%) | 9 (31) | 11 (35) | .7 |
| No response after allograft, n (%) | 8 (28) | 4 (13) | .3 |
| 2 years overall survival, % (95% CI) | 18 (0-38) | 67 (51-83) | .03 |
| 2 years event-free survival, % (95% CI) | 18 (1-35) | 42 (24-60) | .05 |
| Cumulative incidence of relapse, % (95% CI) | 77 (57-97) | 44 (22-66) | < .001 |
| 1 year treatment-related mortality, % (95% CI) | 18 (4-32) | 24 (10-38) | .4 |